• Something wrong with this record ?

Diagnostic and prognostic value of placental growth factor serum concentration in clear cell renal cell carcinoma

M. Cechova, M. Chocholaty, M. Babjuk, T. Zima, K. Havlova, M. Koldova, M. Schmidt, M. Kalousova

. 2021 ; 165 (4) : 375-379. [pub] 20210222

Language English Country Czech Republic

Document type Journal Article

BACKGROUND AND AIM: Placental Growth Factor (PlGF) plays a crucial role in angiogenesis and was identified as a potential prognostic biomarker in various types of cancer. Therefore, we evaluated the diagnostic accuracy and prognostic value of PlGF serum concentration in patients with clear cell renal cell carcinoma (ccRCC). PATIENTS AND METHODS: A total of 49 patients subjected to partial or radical nephrectomy for ccRCC [localized without relapse (lccRCC; n=31), localized with later relapse (rccRCC; n=8), primary metastatic cancer (mccRCC; n=10); median of follow-up 4.4 years] were enrolled in a prospective study to assess the significance of PlGF serum concentration. PlGF was measured prior to surgery and 3 months postoperatively. Our control group consisted of 38 healthy subjects. RESULTS: PlGF serum concentration was significantly higher in ccRCC compared to controls (P=0.002). The cut-off value of PlGF concentration for the risk of ccRCC was determined at 12.71 pg/mL (AUC=0.729; P=0.0001). Prior to surgery, among ccRCC subgroups, significantly higher PlGF concentration was detected in mccRCC compared to lccRCC (P=0.002). Postoperatively, we observed a tendency to higher PlGF serum concentration in rccRCC compared to lccRCC subgroup, however without significance (P=0.17). The cut-off value for the risk of relapse was 11.41 pg/mL (AUC=0.792; P=0.0003). In subjects with localized ccRCC with PlGF concentration below 11.41 pg/mL 3-years cancer specific survival was 93% compared to 61% in subject with concentration above the cut-off value (P=0.018). CONCLUSION: Based on our findings, PlGF serum concentration seems to be a useful biomarker in diagnostics and prediction of prognosis in ccRCC.

References provided by Crossref.org

Bibliography, etc.

Literatura

000      
00000naa a2200000 a 4500
001      
bmc22007888
003      
CZ-PrNML
005      
20220429095119.0
007      
ta
008      
220309s2021 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2021.003 $2 doi
035    __
$a (PubMed)33612835
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Koldová, Markéta $7 xx0272359 $u Department of Urology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
245    10
$a Diagnostic and prognostic value of placental growth factor serum concentration in clear cell renal cell carcinoma / $c M. Cechova, M. Chocholaty, M. Babjuk, T. Zima, K. Havlova, M. Koldova, M. Schmidt, M. Kalousova
504    __
$a Literatura
520    9_
$a BACKGROUND AND AIM: Placental Growth Factor (PlGF) plays a crucial role in angiogenesis and was identified as a potential prognostic biomarker in various types of cancer. Therefore, we evaluated the diagnostic accuracy and prognostic value of PlGF serum concentration in patients with clear cell renal cell carcinoma (ccRCC). PATIENTS AND METHODS: A total of 49 patients subjected to partial or radical nephrectomy for ccRCC [localized without relapse (lccRCC; n=31), localized with later relapse (rccRCC; n=8), primary metastatic cancer (mccRCC; n=10); median of follow-up 4.4 years] were enrolled in a prospective study to assess the significance of PlGF serum concentration. PlGF was measured prior to surgery and 3 months postoperatively. Our control group consisted of 38 healthy subjects. RESULTS: PlGF serum concentration was significantly higher in ccRCC compared to controls (P=0.002). The cut-off value of PlGF concentration for the risk of ccRCC was determined at 12.71 pg/mL (AUC=0.729; P=0.0001). Prior to surgery, among ccRCC subgroups, significantly higher PlGF concentration was detected in mccRCC compared to lccRCC (P=0.002). Postoperatively, we observed a tendency to higher PlGF serum concentration in rccRCC compared to lccRCC subgroup, however without significance (P=0.17). The cut-off value for the risk of relapse was 11.41 pg/mL (AUC=0.792; P=0.0003). In subjects with localized ccRCC with PlGF concentration below 11.41 pg/mL 3-years cancer specific survival was 93% compared to 61% in subject with concentration above the cut-off value (P=0.018). CONCLUSION: Based on our findings, PlGF serum concentration seems to be a useful biomarker in diagnostics and prediction of prognosis in ccRCC.
650    _2
$a biologické markery $7 D015415
650    12
$a karcinom z renálních buněk $x diagnóza $7 D002292
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a nádory ledvin $7 D007680
650    _2
$a lokální recidiva nádoru $x diagnóza $7 D009364
650    _2
$a placentární růstový faktor $7 D000072483
650    _2
$a prognóza $7 D011379
650    _2
$a prospektivní studie $7 D011446
655    _2
$a časopisecké články $7 D016428
700    1_
$a Chocholatý, Matúš $7 xx0121519 $u Department of Urology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Babjuk, Marko, $d 1961- $7 jn20020716353 $u Department of Urology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Zima, Tomáš, $d 1966- $7 jn20000620440 $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Havlová, Klára $7 xx0184887 $u Department of Urology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Koldová, Markéta $7 xx0272359 $u Department of Urology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Schmidt, Marek $7 xx0105483 $u Department of Urology, University Hospital Motol and 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Kalousová, Marta, $d 1974- $7 mzk2005318016 $u Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 165, č. 4 (2021), s. 375-379
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33612835 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20220309 $b ABA008
991    __
$a 20220429095111 $b ABA008
999    __
$a ok $b bmc $g 1773018 $s 1159081
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 165 $c 4 $d 375-379 $e 20210222 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20220309

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...